Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 205,361 shares of the pharmaceutical company’s stock after acquiring an additional 12,542 shares during the period. Federated Hermes Inc. owned approximately 0.08% of Vertex Pharmaceuticals worth $83,559,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Arlington Trust Co LLC boosted its stake in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $30,000. Baystate Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 25 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $25,000. Finally, Cornerstone Planning Group LLC acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $33,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on VRTX shares. Truist Financial lifted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Sanford C. Bernstein downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $440.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. Canaccord Genuity Group downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and boosted their target price for the company from $332.00 to $379.00 in a research report on Wednesday, January 24th. Finally, StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 12th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $429.45.

Vertex Pharmaceuticals Stock Up 0.1 %

VRTX opened at $393.48 on Friday. Vertex Pharmaceuticals Incorporated has a twelve month low of $316.43 and a twelve month high of $448.40. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $414.17 and a 200 day moving average price of $396.74. The company has a market cap of $101.70 billion, a PE ratio of 28.33, a price-to-earnings-growth ratio of 1.85 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the firm earned $3.33 EPS. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Kristen Ambrose sold 1,374 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $577,409.76. Following the completion of the sale, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at approximately $4,066,242.24. The disclosure for this sale can be found here. Insiders sold a total of 12,381 shares of company stock worth $5,203,249 in the last 90 days. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.